Stockscreener 앱 받기
0.00
100.00%
-0.157
시간 외 거래:
.15
0.15
+
전일 마감가:
$0.157
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$11.00M
수익:
$1.16M
순이익/손실:
$-39.74M
주가수익비율:
0.00
EPS:
-0.62
순현금흐름:
$-35.02M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
명칭
Glycomimetics Inc
전화
240-243-1201
주소
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
GLYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.00 | 11.00M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Glycomimetics Inc 주식(GLYC)의 최신 뉴스
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - MarketScreener
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Crescent Biopharma Completes Merger With GlycoMimetics - MarketScreener
Balance Sheet Dive: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Crescent Biopharma Completes Closing of Merger with GlycoMimetic - GuruFocus
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million | CBIO Stock News - GuruFocus
Crescent Biopharma Completes Closing of Merger with - GlobeNewswire
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced ... - Bluefield Daily Telegraph
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
GlycoMimetics, Inc. Announces Board Changes - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - MarketScreener
GlycoMimetics Announces Chief Executive Officer Changes - MarketScreener
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Sto - GuruFocus
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Stock News - GuruFocus
Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World
GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World
Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister
Wellington Management Group LLP Takes Position in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals - marketscreener.com
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals - citybiz
GlycoMimetics (GLYC) Stockholders Approve Merger with Crescent Biopharma | GLYC Stock News - GuruFocus
GlycoMimetics announces 1-for-100 reverse stock split - Investing.com Australia
GlycoMimetics announces 1-for-100 reverse stock split By Investing.com - Investing.com Canada
GlycoMimetics stockholders approve proposed Crescent Biopharma merger - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire
GlycoMimetics Announces Merger Amidst Uncertainties - TipRanks
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference - The Manila Times
GlycoMimetics executives to depart amid merger plans - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - marketscreener.com
GlycoMimetics: Q1 Earnings Snapshot - CT Insider
GLYCOMIMETICS INC SEC 10-Q Report - TradingView
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerGLYC, BRZH, PRA, FVNNU - The Malaysian Reserve
GLYCGlycomimetics Latest Stock News & Market Updates - Stock Titan
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
Glycomimetics Inc (GLYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Glycomimetics Inc 주식 (GLYC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
0.39%
0.42%
자본화:
|
볼륨(24시간):